Medidata Solutions (MDSO) Getting Somewhat Positive Media Coverage, Report Finds
Media stories about Medidata Solutions (NASDAQ:MDSO) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medidata Solutions earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.8530185399843 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of equities research analysts have recently weighed in on the stock. Piper Jaffray Companies boosted their price objective on shares of Medidata Solutions to $98.00 and gave the company an “overweight” rating in a report on Wednesday, May 23rd. Needham & Company LLC lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, July 25th. Morgan Stanley reissued an “equal weight” rating on shares of Medidata Solutions in a report on Friday, June 1st. Deutsche Bank boosted their price objective on shares of Medidata Solutions from $85.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, June 13th. Finally, ValuEngine raised shares of Medidata Solutions from a “hold” rating to a “buy” rating in a report on Friday, August 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Medidata Solutions currently has an average rating of “Buy” and an average price target of $87.62.
Shares of MDSO opened at $84.02 on Friday. The firm has a market cap of $4.92 billion, a PE ratio of 98.85, a P/E/G ratio of 5.16 and a beta of 1.40. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.41 and a current ratio of 1.41. Medidata Solutions has a 1-year low of $59.60 and a 1-year high of $88.87.
In other Medidata Solutions news, CFO Rouven Bergmann sold 3,000 shares of the company’s stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $82.85, for a total value of $248,550.00. Following the sale, the chief financial officer now directly owns 81,642 shares of the company’s stock, valued at $6,764,039.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert Taylor sold 5,000 shares of the company’s stock in a transaction on Tuesday, July 31st. The shares were sold at an average price of $73.05, for a total transaction of $365,250.00. Following the completion of the sale, the director now directly owns 44,036 shares in the company, valued at $3,216,829.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,418 shares of company stock worth $2,860,168. 4.70% of the stock is owned by corporate insiders.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.